Taken together, our findings reveal the previously unrecognized tumor-promoting function of CDK4/6-DUB3 axis through stabilizing YAP1, providing preclinical evidence that targeting this axis may represent a promising therapeutic strategy for HCC. This evidence concerns the gene CDK4 and neoplasm.